In: Columbus Venture Partners
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
04/05/2017Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases Paris,... Read More
Damià Tormo Carulla, 2017 Princess of Girona Foundation Business Award
06/04/2017Damià Tormo Carulla, 2017 Princess of Girona Foundation Business Award Girona, Spain, April 6th 2017 - The winner was chosen for combining... Read More
Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma
30/03/2017Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment... Read More
Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma
06/02/2017Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma Cambridge, USA,... Read More
Quirónsalud will establish the first center for proton therapy in Spain
04/01/2017Quirónsalud will establish the first center for proton therapy in Spain Madrid, Spain, 4th January 2017 - Quirónsalud, in its compromise... Read More
PTS Closes out a round of 1.3M Euros of funding
18/10/2016PTS Closes out a round of 1.3M Euros of funding Valencia, Spain, 18th October 2016 - Polypeptide Therapeutic Solutions SL (PTS)... Read More
Aura Bioscience Inc. closes out a new round of $8M of funding
18/10/2016Cambridge, USA, 18th October 2016 – In September Aura Bioscience Inc. (Aura) closed out a funding round worth 8 million dollars led by…
Read MoreAura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board
29/09/2016Cambridge, USA, 29th September 2016 – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells…
Read MoreColumbus Venture Partners SGEIC comes to life
30/01/2016Damià Tormo Carulla and Javier García Cogorro have already received the approval of the CNMV for Columbus Venture Partners Investment Management…
Read MoreColumbus Venture Partners launches a fund for biotech firms
30/01/2016Columbus Venture Partners launches a fund for biotech firms. Read the full article.
Read More